VALLEY COTTAGE, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including,
- Development of natural product interventions for chemotherapy-induced side effects
- Growing implementation of radiation treatment in cancer treatment owing to the associated high success rate of chemotherapy
- Growing R&D investments in cancer research
The FMI study finds that ‘growth factor’ drugs continued to garner highest revenues in the chemotherapy-induced myelosuppression treatment market . In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors. Gains were especially notable for granulocyte-colony stimulating factor or G-CSF, which accounted for over 60% of the global chemotherapy-induced myelosuppression treatment market revenues in 2018.
The FMI study reveals that erythropoietin-stimulating agents (ESA) also accounted for a significant market share, with revenues likely to grow at 2.8% in 2019. In April 2017, FDA announced the removal of risk evaluation and mitigation strategy (REMS) requirement for the use of ESA drugs in myelosuppression treatment. The ESAs used in the treatment of radiation-induced myelosuppression treatment are epoetin alfa and darbepoetin alfa. This has led healthcare professionals to engage in the practice of discussing benefits as well as risks of treatments that include ESAs before initiating the use.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/...ep-gb-1364
Hematopoietic growth factors have transformed the practice of cancer treatment by allowing stimulation of production of specific cells. With this, use of thrombopoietin receptor agonists is expected to rise rapidly at the rate of 3.5% in 2019.
Injectable Drugs Present Higher Therapeutic Availability over Orals
The FMI study finds that injectable drugs accounted for over 97% of the chemotherapy-induced myelosuppression treatment market revenues in 2018. The status-quo will continue in the future, however, the oral route of administration is expected to garner increasing annual revenues and expected to grow at 4.8% in 2019 over 2018.
Increasing number of research validations related to the benefits of the oral route of administration can be attributed to the higher growth rate of the segment in the future. However, revenues from the injectable route of the administration continue to grow steadily on the back of their higher therapeutic availability over orally administered drugs.
Market Revenues Consolidated in Neutropenia Treatment
According to the study, chemotherapy-induced myelosuppression treatment market revenues heavily consolidated in the neutropenia treatment. In 2018, neutropenia indication accounted for over 62% of market revenues. As neutropenia is one of the most common side effects of chemotherapy wherein prolongation of the same can lead to life-threatening infections. Owing to the severity of the implications, chemotherapy-induced myelosuppression therapeutics are heavily used in the treatment of neutropenia.
Anemia and thrombocytopenia indications also utilize chemotherapy-induced myelosuppression treatment therapeutics. The study finds that revenues in the thrombocytopenia treatment will grow at 3.7% y-o-y in 2019.
Preview Analysis On Global Chemotherapy-Induced Myelosuppression Treatment Market Segmentation by By Drug Class (Growth Factors, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonists, Erythropoietin-stimulating Agents, Thrombopoietic Agents, Iron supplementation, Others); By Route of Administration (Oral, Injectable); By Indication (Anemia, Neutropenia, Thrombocytopenia): https://www.futuremarketinsights.com/reports/...ent-market
Retail Pharmacies Most Prominent Sales Channel
The study opines that chemotherapy-induced myelosuppression treatment therapeutics sales remain higher through retail pharmacies. Suppliers of these therapeutics have extensive distribution network with international retail pharmacies. Due to this, retail pharmacies accounted for over 48% of the chemotherapy-induced myelosuppression treatment market revenues in 2018.
Owing to heavy integration of pharmacies in the hospitals, distribution of chemotherapy-induced myelosuppression treatment therapeutics through hospital pharmacies also account for a considerable share of the market revenues. The study finds that hospital pharmacies can be called the second largest distributor of chemotherapy-induced myelosuppression treatment therapeutics owing to their 45% of the market revenues.
US – The World’s Largest Chemotherapy-induced Myelosupression Treatment Market
FMI reveals that North America accounted for over 82% of the revenues in chemotherapy-induced myelosuppression treatment market in 2018. Presence of leading cancer therapeutics providers, significant R&D investments and established healthcare sector contribute to the bulk of market revenues. The U.S. remains the largest consumer of the chemotherapy-induced myelosuppression treatment market.
Market revenues in the APEJ region are likely to grow at higher rate owing to improving healthcare facility and growing penetration of advanced cancer care treatments. China, followed by India, accounts for the highest market revenues in APEJ owing to improving economic scenario and developing healthcare infrastructure.
Request Report TOC @ https://www.futuremarketinsights.com/askus/rep-gb-1364
More from Healthcare, Pharmaceuticals and Medical Devices Market
Retinal Biologics Market Segmentation by Drug Class (VEGF-An antagonist, TNF-α inhibitor); by Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Uveitis, Others); by Distributional Channel (Institutional Sales, Retail Sales): https://www.futuremarketinsights.com/reports/...ics-market
Brain Monitoring System Market Segmentation By Product Type (Functional Near-Infrared Spectroscopy (fNIRS), Electroencephalography (EEG) Systems, Magnetoencephalography (MEG) Systems, MRI Systems, Other Brain Monitoring Systems); By Modality (Portable/Handheld Systems, Standalone Systems); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Pediatric & Neonatal Intensive care Units): https://www.futuremarketinsights.com/reports/...tem-market
3D Cell Culture Market Segmentation By Product Type (Scaffold-Free 3D Cell Culture, Scaffold-Based 3D Cell Culture); By Applications (Drug Discovery, Tissue Regeneration & Regenerative Medicines, Cancer Research, Stem Cell Technology, Others); By End User (Biotechnology and Pharmaceuticals Industries, Hospital Laboratories, Academic Research Institutes, Contract Research Organizations): https://www.futuremarketinsights.com/reports/...ure-market
About Us
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Browse More Healthcare, Pharmaceuticals and Medical Devices Market Insights
Contact Us
Mr. Sudip Saha Future Market Insights 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F : +1-845-579-5705 T (UK): + 44 (0) 20 7692 8790 Sales: sales@futuremarketinsights.com Press Office : Press@futuremarketinsights.com Blog: Market Research Blog Website : https://www.futuremarketinsights.com/
